Q5107 HCPCS Level II code: Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Q5107 is the HCPCS code for “Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Short description: Inj mvasi 10 mg
HCPCS · United States
Notes for Q5107
As CMS prints them, with any note Q5107 takes from the headings above it.
Note
- CMS processing note 0187: PUB. 100-4, CHAPTER 17.
Medicare details
The indicators CMS publishes with Q5107 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2019
Where Q5107 sits
- 1Q codesTemporary codes
- 2Active code Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q5107 mean?
Q5107 is the HCPCS code for “Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q5107?
CMS lists Q5107’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q5107
All Q codesQ5101Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgramQ5102Injection, infliximab, biosimilar, 10 mgQ5103Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mgQ5104Injection, infliximab-abda, biosimilar, (renflexis), 10 mgQ5105Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 unitsQ5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 unitsQ5108Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mgQ5109Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mgQ5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgramQ5111Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mgQ5112Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mgQ5113Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg